Cargando…

Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer

Objective: To evaluate the efficacy and treatment rationale of Hürthle cell carcinoma (HCC) following a patient with progressive and metastatic HCC. HCC was recently shown to harbor a distinct genetic make-up and the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kiase (PI3K)/AKT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aydemirli, Mehtap Derya, Corver, Willem, Beuk, Ruben, Roepman, Paul, Solleveld-Westerink, Nienke, van Wezel, Tom, Kapiteijn, Ellen, Morreau, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721552/ https://www.ncbi.nlm.nih.gov/pubmed/31443247 http://dx.doi.org/10.3390/cancers11081185

Ejemplares similares

Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
por: Addie, Ruben D., et al.
Publicado: (2020)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma)
por: Yang, Qiong, et al.
Publicado: (2019)

Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
por: Aydemirli, M. D., et al.
Publicado: (2019)

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Clinical implications of follicular and Hurthle cell carcinoma in an iodine-sufficient area
por: Shin, Dong Yeob, et al.
Publicado: (2014)

Hurthle Cells Adenoma With Distant Metastases Refractory to Radioiodine
por: Rosario, Pedro Weslley, et al.
Publicado: (2021)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
por: McFarland, Daniel C, et al.
Publicado: (2014)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer
por: Fordham, Beth A, et al.
Publicado: (2015)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023)

Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
por: Oh, Ji Min, et al.
Publicado: (2022)

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
por: Mohamed, Ateesha F., et al.
Publicado: (2015)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Treating Hyperthyroidism with Radioactive Iodine
por: Harding, L K
Publicado: (1993)

Radioactive iodine and female fertility
por: Navarro, Pino, et al.
Publicado: (2022)

Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data
por: Kim, Won Gu, et al.
Publicado: (2014)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
por: Collina, Francesca, et al.
Publicado: (2019)

Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report
por: Shirode, Parth S, et al.
Publicado: (2023)

Thyroid FNAC containing hürthle cells and hürthle-like cells: A study of 128 cases
por: Yazgan, Aylin, et al.
Publicado: (2016)

Iodine Uptake in Retroperitoneal Cysts after Radioactive Iodine Treatment
por: Lee, Ji Young, et al.
Publicado: (2020)

Insulin pump exposed to radioactive iodine
por: Magdaleno, Angela L., et al.
Publicado: (2018)

Radioactive Iodine Therapy and Glucose Tolerance
por: Samadi, Roghaieh, et al.
Publicado: (2017)

Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid
por: Máximo, Valdemar, et al.
Publicado: (2004)

Genome Haploidisation with Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma
por: Corver, Willem E., et al.
Publicado: (2012)

Hürthle cell carcinoma: current perspectives
por: Ahmadi, Sara, et al.
Publicado: (2016)

Challenges in Cytology Specimens With Hürthle Cells
por: Thodou, Eleni, et al.
Publicado: (2021)

Measurements on electromagnetically-separated radioactive isotopes of iodine
por: Aagaard, P, et al.
Publicado: (1957)

Impact of lithium on radioactive iodine therapy for hyperthyroidism
por: Lingudu, Brahmanandam, et al.
Publicado: (2014)

Reproducibility of radioactive iodine uptake (RAIU) measurements
por: Pelletier‐Galarneau, Matthieu, et al.
Publicado: (2017)

APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma
por: Siraj, Sarah, et al.
Publicado: (2022)

Clinical role of (18)F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer
por: Tang, Xiaowei, et al.
Publicado: (2023)

Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non‐medullary thyroid cancer
por: Crezee, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4d8o03r7v0qe9i3ejgcejbffr